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Objectives:  To  assess  the  ability  of  different  technology  platforms  to detect  epidermal  growth  factor  recep-
tor  (EGFR)  mutations,  including  T790M,  from  circulating  tumor  DNA  (ctDNA)  in advanced  non-small  cell
lung cancer  (NSCLC)  patients.
Materials  and methods:  A  comparison  of  multiple  platforms  for  detecting  EGFR  mutations  in plasma
ctDNA  was  undertaken.  Plasma  samples  were  collected  from  patients  entering  the  ongoing  AURA  trial
(NCT01802632),  investigating  the safety,  tolerability,  and  efﬁcacy  of  AZD9291  in patients  with  EGFR-
sensitizing  mutation-positive  NSCLC.  Plasma  was  collected  prior  to AZD9291  dosing  but following  clinical
progression  on a previous  EGFR-tyrosine  kinase  inhibitor  (TKI).  Extracted  ctDNA  was  analyzed  using
two  non-digital  platforms  (cobas® EGFR  Mutation  Test  and  therascreenTM EGFR  ampliﬁcation  refrac-
tory  mutation  system  assay)  and  two  digital  platforms  (Droplet  DigitalTM PCR  and  BEAMing  digital  PCR
[dPCR]).
Results:  Preliminary  assessment  (38 samples)  was conducted  using  all four  platforms.  For  EGFR-TKI-
sensitizing  mutations,  high  sensitivity  (78–100%)  and speciﬁcity  (93–100%)  were  observed  using  tissue
as  a non-reference  standard.  For  the  T790M  mutation,  the  digital  platforms  outperformed  the  non-digital
platforms.  Subsequent  assessment  using  72  additional  baseline  plasma  samples  was  conducted  using
the  cobas® EGFR  Mutation  Test  and  BEAMing  dPCR.  The  two platforms  demonstrated  high sensitivity
(82–87%)  and  speciﬁcity  (97%)  for EGFR-sensitizing  mutations.  For  the  T790M  mutation,  the sensitivity
and  speciﬁcity  were  73%  and  67%,  respectively,  with  the  cobas® EGFR  Mutation  Test,  and  81%  and  58%,
respectively,  with  BEAMing  dPCR. Concordance  between  the  platforms  was  >90%,  showing  that  multiple
platforms  are  capable  of  sensitive  and  speciﬁc  detection  of  EGFR-TKI-sensitizing  mutations  from  NSCLC
patient  plasma.
Conclusion:  The  cobas® EGFR  Mutation  Test  and  BEAMing  dPCR  demonstrate  a high sensitivity  for  T790M
mutation  detection.  Genomic  heterogeneity  of  T790M-mediated  resistance  may  explain  the  reduced
speciﬁcity  observed  with  plasm
the  use  of both  platforms  in th
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. Introduction
Nearly all patients with non-small cell lung cancer (NSCLC)
ho initially respond to epidermal growth factor receptor (EGFR)-
yrosine kinase inhibitor (TKI) therapy develop resistance. In such
atients, it is now recommended to obtain a biopsy in order to char-
cterize the mechanism of resistance. However, obtaining sufﬁcient
issue for mutation analysis in patients with advanced disease
s challenging, as invasive interventions may  be ineffective and
nsafe. Moreover, detection of disease-relevant mutations from the
iopsy of a single tumor lesion may  not be reﬂective of the patient’s
omplete disease burden, especially in heterogeneous cancers [1,2].
In recent years, circulating tumor DNA (ctDNA) has emerged
s a speciﬁc and sensitive blood-based biomarker for detection of
GFR mutations. T790M is the most common mechanism of resis-
ance to ﬁrst-line EGFR-TKIs, detectable in nearly 60% of tissue
iopsies taken after resistance develops [3,4]. Although the mech-
nism by which ctDNA is released into the bloodstream is unclear
5], it is thought to be related to physiological events related to
he tumor cells, including apoptosis and necrosis [6]. Several stud-
es have demonstrated that mutations, including the EGFR T790M
utation, detected in plasma ctDNA are highly concordant with
hose detected in tumor tissue in patients [7–12], indicating that
tDNA as a liquid biopsy is a feasible and minimally invasive alter-
ative to tissue biopsy. Other clinical applications for ctDNA in
his setting include molecular assessment of patients at diagnosis
11], serial (real-time) monitoring of patients for the develop-
ent of resistance mutations (which is not practical/possible
ith repeat biopsies) [11,13], and for the clinical management
f patients [14]. Importantly, because ctDNA analysis does not
nvolve formaldehyde ﬁxation, there is reduced frequency of a false
ositive result due to deamination [15]. Although several method-
logies are available for mutation analysis from ctDNA, including
igital polymerase chain reaction (dPCR), mutant-enriched PCR,
nd peptide nucleic acid-locked nucleic acid PCR [16], there is
 paucity of widely accepted and approved methods for ctDNA
nalysis.
AZD9291 is a highly selective, irreversible EGFR-TKI that tar-
ets both EGFR-TKI-sensitizing mutations (e.g., exon 19 deletion
nd L858R) and the T790M resistance mutation [17]. AZD9291 has
hown promising clinical activity in the ongoing phase I AURA
rial (clinicaltrials. gov. identiﬁer: NCT01802632) in patients with
GFR-TKI-resistant advanced NSCLC [18]. To date, patients have
een selected for AURA trials using tissue testing for the T790M
esistance mutation with the cobas® EGFR Mutation Test (Roche
olecular Systems, Inc., Pleasanton, CA, USA), the companion diag-
ostic being developed for AZD9291. However, as part of the clinical
evelopment process for AZD9291, alternative selection strate-
ies are also being evaluated, namely EGFR mutation testing using
lasma ctDNA. To this end, a comparison was undertaken of mul-
iple platforms for the detection of EGFR mutations in plasma




Plasma samples were collected from patients enrolled in the
ngoing phase I AURA study. In brief, AURA (NCT01802632) is
n open-label, multicenter study designed to assess the safety,
olerability, and efﬁcacy of AZD9291 in patients with EGFR
utation-positive NSCLC who have progressed following prior
herapy with an EGFR-TKI agent [18]. All patients had mea-
urable disease at baseline, with radiological documentation ofer 90 (2015) 509–515
disease progression while receiving continuous treatment with an
EGFR-TKI. Patients were required to have EGFRm-positive NSCLC,
conﬁrmed by either the presence of a tumor harboring an EGFR
mutation known to be associated with EGFR-TKI sensitivity, or
evidence of a clinical beneﬁt with an EGFR-TKI, followed by sys-
temic objective progression (according to Response Evaluation
Criteria In Solid Tumors or World Health Organization criteria)
while on continuous EGFR-TKI treatment as per Jackman criteria
[19].
2.2. Ethics statement
The study was  conducted in accordance with the Declara-
tion of Helsinki, the International Conference on Harmonisa-
tion/Good Clinical Practice, applicable regulatory requirements,
and AstraZeneca’s policy on bioethics. All patients provide written
informed consent before any study-speciﬁc procedures, sampling,
and analyses.
The AURA protocol was  reviewed and approved by Institutional
Review Boards at each trial site before patient enrollment.
2.3. Plasma sample collection and DNA extraction
Plasma samples were collected from patients enrolled into
AURA, following progression on a previous EGFR-TKI, but prior to
dosing with AZD9291; samples were taken from patients in both
dose escalation and dose expansion cohorts. Plasma samples from
identical timepoints were pooled per patient and 2 ml  (where avail-
able) were assigned for each platform assessment; samples were
stored at −80 ◦C and were tested in a blinded fashion.
Patient-matched tumor material (formalin-ﬁxed and parafﬁn-
embedded) was  available for 80% of plasma samples to enable
ctDNA–tumor concordance testing. Tumor tissue originated from
pre-study biopsies collected following progression on the last line
of therapy. Tumor tissue genotyping was  conducted in one of three
central laboratories using a standardized cobas® EGFR Mutation
Test assay (Roche Molecular Systems, Inc.), but with a protocol
modiﬁcation that allowed the testing laboratories to use more
slides than stated in the package insert if it was  thought to be
deemed necessary. In the dose expansion cohorts, T790M muta-
tion status was identiﬁed either locally or centrally; all local results
were conﬁrmed by a mandatory retrospective centralized tissue
result for each patient; in the dose escalation cohorts, a central tis-
sue test was  not required but a local EGFRm tissue mutation result
was available for most patients.
The sensitivity of the plasma assays was calculated as follows:
100% × true positives/(true positives + false negatives), where true
positives and false negatives were deﬁned according to the tissue-
based test. The speciﬁcity of the plasma assays was calculated
as follows: 100% × true negatives/(false positives + true negatives),
where true negatives and false positives were deﬁned according
to the tissue-based test [20]. Overall concordance between each
plasma assay and the tissue-based test was also calculated.
2.4. Mutation detection
Extracted ctDNA was  tested for three common EGFR mutations
(exon 19 deletion, L858R, and T790M) using multiple platforms.
This involved non-digital detection using the cobas® EGFR Muta-
tion Test and the therascreenTM EGFR ampliﬁcation refractory
mutation system (ARMS) assay (QIAGEN, Venlo, The Netherlands)
and digital detection using the highly sensitive and quantitative
Droplet Digital PCR (ddPCRTM; Bio-Rad/MolecularMD, Hercules,
CA, USA) and beads, emulsions, ampliﬁcation, and magnetics
(BEAM)ing dPCR technique (Sysmex Inostics, Inc., Mundelein, IL,
USA).
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Fig. 1. Relationship of T790M plasma detectiona to NSCLC disease classiﬁcation.
**P  < 0.01; refers to the presence of T790M positive mutations in M1a/M0 versus M1b  pat
ctDNA, circulating tumor DNA; ddPCR, Droplet Digital PCR; M1a/M0, disease conﬁned to
lung  cancer.
Table 1
Performance of four different plasma assays, using a tissuea test result as a non-
reference standard, for detection of EGFR mutations from circulating tumor DNA in










Sensitivity 86% 82% –b 93%
(24/28) (23/28) (26/28)
Speciﬁcity 100% 100% –b 100%
(10/10) (10/10) (10/10)
Concordance 89% 87% –b 95%
L858R
Sensitivity 90% 78% 90% 100%
(9/10) (7/9) (9/10) (10/10)
Speciﬁcity 100% 100% 100% 93%
(28/28) (28/28) (28/28) (26/28)
Concordance 97% 95% 97% 95%
T790M
Sensitivity 41% 29% 71% 71%
(7/17) (5/17) (12/17) (12/17)
Speciﬁcity 100% 100% 83% 67%
(6/6) (6/6) (5/6) (4/6)
Concordance 57% 48% 74% 70%
ARMS, ampliﬁcation refractory mutation system; dPCR, digital polymerase chain
reaction; ddPCR, Droplet Digital polymerase chain reaction; EGFR, epidermal growth
factor receptor; PCR, polymerase chain reaction.











T790M mutations were more readily detected in the plasma ofested via central assays.
b Comprehensive exon 19 deletion data not available.
Assays were performed according to each manufacturer’s pro-
ocols unless otherwise stated. Testing on the cobas® z 480
nalyzer and therascreenTM platform was performed internally
t AstraZeneca, with analysis of cobas® EGFR Mutation Test data
erformed by Roche using algorithms speciﬁc for ctDNA testing.
peciﬁcally, for the cobas® EGFR Mutation Test, DNA was extracted
rom plasma using the cobas® cfDNA Sample Preparation Kit (Roche
olecular Systems, Inc.). Extracted DNA was assayed for mutation
tatus using the protocol speciﬁc for cfDNA, with the cobas® EGFR
utation Test.ients. aAs determined by ddPCR assay (Bio-Rad/MolecularMD).
 the thoracic cavity; M1b, extra-thoracic metastatic disease; NSCLC, non-small cell
For the therascreenTM assay, DNA was  extracted from plasma
as described in the QIAamp Circulating Nucleic Acid Handbook,
second edition (QIAGEN) using the protocol, puriﬁcation of circu-
lating nucleic acids from 1 ml,  2 ml,  or 3 ml  plasma. Modiﬁcations of
the protocol and speciﬁc details are as follows: samples were cen-
trifuged at 3000 rpm for 2 min  and the supernatant was  transferred
to a clean tube, prior to extraction (step 3); a brief centrifuge spin
was performed after the 60 ◦C incubation (step 4); 55 l buffer AVE
was added at the elution step 15; DNA was stored at −80 ◦C. Prior
to mutation testing, all samples were assessed for total ampliﬁable
DNA and subsequently processed for the detection of EGFR muta-
tions and data analysis using the therascreenTM EGFR RGQ PCR Kit
Handbook version 1 (QIAGEN); a minor protocol modiﬁcation was
that 16 samples per run were tested.
Testing on the ddPCRTM and BEAMing dPCR platforms was per-
formed at MolecularMD (Cambridge, MA,  USA) and Sysmex Inostics
(Hamburg, Germany), respectively.
3. Results
3.1. Initial platform comparison (n = 38)
A preliminary assessment using all four platforms was  per-
formed with 38 plasma samples. High sensitivity and speciﬁcity,
using a tissue test result as a non-reference standard, was observed
with the cobas® EGFR Mutation Test, the therascreenTM EGFR
ARMS assay, and the BEAMing dPCR for EGFR-sensitizing muta-
tions (Table 1). The same was  true with the ddPCRTM for the L858R
EGFR mutation. No sensitivity or speciﬁcity data were available for
the exon 19 deletion mutation for the ddPCRTM (Table 1) as it was
only designed to detect a minority of known exon 19 deletions.
Digital platforms appeared to detect a higher percentage of
T790M mutations, compared with non-digital platforms (Table 1).
In the single case where ddPCRTM detected a positive T790M muta-
tion that was  not detected in the tissue sample, BEAMing dPCR also
classiﬁed this sample as T790M positive.patients with extra-thoracic metastatic disease (M1b) than patients
with disease conﬁned to the thoracic cavity (M1a/M0) (P < 0.01;
Fig. 1).
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Table 2
Performance of two  different plasma assays relative to using a tissue test result as a
non-reference standard for detection of epidermal growth factor receptor mutations
from circulating tumor DNA in a set of 72 plasma samplesa from the AURA clinical
trial.
cobas® EGFR Mutation Test BEAMing dPCR
Exon 19 deletion
Sensitivity 82% (23/28) 82% (23/28)
Speciﬁcity 97% (30/31) 97% (30/31)
L858R
Sensitivity 87% (20/23) 87% (20/23)
Speciﬁcity 97% (35/36) 97% (35/36)
T790M
Sensitivity 73% (30/41) 81% (33/41)
Speciﬁcity 67% (16/24) 58% (14/24)
BEAM, beads, emulsions, ampliﬁcation, and magnetics; dPCR, digital polymerase
chain reaction; EGFR, epidermal growth factor receptor.
a 13 with no exon 19 deletion/L858R tissue result and seven with no T790M tissue
result.
Table 3
Concordance between two different plasma assays for detection of EGFR mutations








































Discordant results with two  different plasma assays for detection of the EGFR T790M



















2  Positive Positive
(0.048%)
Negative
3  Positive Positive
(0.064%)
Negative
4  Positive Positive
(0.202%)
Negative
5  Positive Negative Negative
6 Positive Negative Negative
7 Positive Negative Negative
8 Positive Negative Negative
9 Positive Negative Negative
10 Positive Negative Negative
































T790M mutation; good speciﬁcity was also achieved with these twoPCR, digital polymerase chain reaction; EGFR, epidermal growth factor receptor.
.2. Subsequent platform comparison (n = 72)
A subsequent assessment using two of the original four plat-
orms was performed with a set of distinct baseline plasma samples
rom 72 additional, non-overlapping patients on the AURA trial. Of
he digital platforms, BEAMing PCR was selected for further test-
ng as ddPCRTM did not allow a full assessment of EGFR mutations.
f the non-digital platforms, the cobas® EGFR Mutation Test was
elected for further testing as the therascreenTM EGFR ARMS-PCR
ad a lower sensitivity observed for T790M. Subsequent testing
sing the cobas® EGFR Mutation Test was conducted at Roche
olecular Systems, Inc. while BEAMing PCR testing continued to
e done at Sysmex Inostics.
As seen in the initial comparison, high sensitivity and speciﬁcity
ere observed with the cobas® EGFR Mutation Test and BEAMing
PCR for EGFR-TKI-sensitizing mutations (Table 2). Both the cobas®
GFR Mutation Test and BEAMing dPCR demonstrated good sensi-
ivity for T790M mutation detection (Table 2). As observed in the
nitial comparison, BEAMing dPCR showed high sensitivity (81%)
ut a lower speciﬁcity (58%). The sensitivity of the cobas® EGFR
utation Test was markedly improved compared with the initial
omparison (Table 2).
Strong overall concordance was demonstrated between the
obas® EGFR Mutation Test and BEAMing dPCR for detection of
GFR mutations from ctDNA (Table 3).
An analysis of the 20 discordant T790M results was undertaken.
here were four ‘false’ plasma negative results detected by the
obas® EGFR Mutation Test; all four were called positive by BEAM-
ng, but three of these were very near the lower limit of detection
0.020% mutant) (Table 4). There were seven cases where both
lasma assays did not detect any T790M mutation despite a posi-
ive result in the patient matched tumor tissue. Finally, there were
ine ‘false’ plasma positives detected by BEAMing dPCR; seven of
hese were also scored positive by the cobas® EGFR Mutation Test
Table 4).BEAM, beads, emulsions, ampliﬁcation, and magnetics; dPCR, digital polymerase
chain reaction; EGFR, epidermal growth factor receptor.
a Central T790M tissue results.
A preliminary assessment of clinical response to AZD9291 as
a function of the T790M resistance mutation detected at baseline
(i.e., prior to initiation of AZD9291 but following the development
of resistance to ﬁrst-line EGFR-TKI) in plasma and tissue is shown in
Fig. 2. The clinical response rate in patients positive for the T790M
mutation in plasma was  almost identical to that for patients posi-
tive for the T790M mutation in tissue (59% vs. 61%).
4. Discussion
Several technologies have been described for the detection of
EGFR mutations using plasma ctDNA. In the current study, four such
technologies were compared, with the aim of identifying robust
platform (s) to support the ongoing AZD9291 clinical development
program. The study was conducted in two  parts: (i) initial com-
parison of four platforms using a small set of plasma samples; (ii)
subsequent comparison of two  platforms using a larger set of addi-
tional plasma samples. All samples (plasma and patient-matched
tumor tissue) originated from patients enrolled in the ongoing
phase I AURA trial. The cross-platform comparison showed that the
cobas® EGFR Mutation Test and BEAMing dPCR had highly concor-
dant results, with high sensitivity (73–81%) for the detection of theplatforms (58–67%). The objective response rate (ORR) to AZD9291
was almost identical in patients positive for the T790M mutation in
plasma and in tissue (both assessed using the cobas® EGFR Muta-
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aR,  complete response; EGFR, epidermal growth factor receptor; PR, partial respon
ion Test). Collectively, these results show that the cobas® EGFR
utation Test and BEAMing dPCR have the potential to identify
atients harboring T790M mutations from plasma ctDNA.
Four platforms were evaluated in the current study. The two
on-digital platforms comprised the cobas® EGFR Mutation Test
nd the therascreenTM EGFR ARMS assay; both of these testing
ethods arise from established tissue tests that have been adapted
or low-DNA-input plasma samples. The cobas® EGFR Mutation
est and the therascreenTM EGFR RGQ PCR test detect 41 [21] and
1 [22] mutations, respectively, in exons 18–21 of the EGFR gene;
mportantly, both tests detect the T790 M mutation. The two  digi-
al platforms were the BioRad ddPCRTM and BEAMing dPCR. Digital
CR methods are purportedly more sensitive than other assays for
utant sequence detection [23] and are fully quantitative, making
hem suitable for quantiﬁcation of longitudinal plasma samples,
hich may  allow for monitoring of disease/mutation evolution over
ime. Both BEAMing and ddPCR were speciﬁcally included as they
ave been used to proﬁle plasma ctDNA for a variety of cancer-
elated mutations [11,23–27]. Although the ddPCRTM generated
omparable T790M results to BEAMing in the initial comparison
f all four platforms, its ability to detect only a minority of known
xon 19 deletions led to its exclusion from the subsequent platform
omparison.
To the best of the authors’ knowledge, this is the ﬁrst comparison
f the cobas® EGFR Mutation Test and BEAMing dPCR to be pub-
ished. The results support the potential use of both platforms for
he detection of EGFR mutations from patient plasma samples. The
obas® EGFR Mutation Test showed high sensitivity for the T790M
utation, and had comparable sensitivity to BEAMing dPCR. An
mprovement in sensitivity was observed with the cobas® EGFR
utation Test between the initial and subsequent comparisons.
he difference in sensitivity between the two  datasets may  be a
esult of the greater sample size in the subsequent comparison and
ptimization of the assay by Roche between comparisons, resulting
n the identiﬁcation of more T790M mutations. As a complemen-
ary approach, because of its quantitative nature, BEAMing dPCR
ay allow for a more detailed assessment of T790M allelic levels
nd potential correlation with clinical response. Such an analysis, stable disease.
with a large patient cohort from AURA is now ongoing and will be
reported elsewhere. BEAMing dPCR may  also be useful for dynamic
monitoring of longitudinal samples where a binary outcome (i.e.,
simply the presence or absence of a signal) is not appropriate.
The T790M resistance mutation was  more frequently detected
in the plasma of patients with metastatic versus locally advanced
disease. This has been observed in a similar study [11], and suggests
that tumor bulk and metastatic status may  impact the presence of
plasma-mutant EGFR and should be further validated in a clinical
setting [11].
AZD9291 is an orally administered EGFR-TKI that is highly
potent against EGFR-TKI-sensitizing mutations and the T790M
resistance mutation, but with a margin of selectivity against wild-
type EGFR activity [17,28]. While currently approved EGFR-TKIs,
including geﬁtinib and erlotinib, are effective in the treatment of
NSCLC, nearly all patients who respond to these treatments will
eventually develop acquired resistance, and approximately 60% of
EGFR-TKI-resistant tumors will carry a T790M mutation in exon
20 [17,28,29]. Treatment strategies in patients with acquired resis-
tance are limited at present; although irreversible EGFR-TKIs such
as afatinib and dacomitinib have been developed, their clinical
utility is limited in the T790M-resistant setting, likely owing to
dose-limiting toxicities associated with non-selective inhibition
of wild-type EGFR [17,28,30,31]. The safety, tolerability, and efﬁ-
cacy of AZD9291 is currently being investigated in the ongoing
AURA program [18]. Preliminary phase I data show that AZD9291
demonstrates promising clinical activity in patients with centrally
conﬁrmed T790M mutation-positive disease (conﬁrmed ORR of
61% across all doses) [18]. In the current study, the clinical ORR
(complete and partial) was almost identical between patients pos-
itive for the T790M mutation in plasma ctDNA and by tissue
genotyping, suggesting that plasma detection T790M mutation
may  be a suitable alternative to tissue biopsies.
Overall, the concordance between the BEAMing dPCR and the
cobas® EGFR Mutation Test was  90% for the T790M mutation. This
high rate of agreement using two  distinct assay platforms run in
a blinded fashion builds conﬁdence in the overall plasma result.
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issue from the 72-patient set reveals that the BEAMing dPCR and
obas® EGFR Mutation Test outcomes were comparable in 14/20
ases. Furthermore, all six of those instances where the plasma
ests disagreed arose in cases where the T790M allelic fraction
as very low (≤0.2%) and perhaps below the detection limit of the
obas® EGFR Mutation Test plasma assay. Taken together, these
ata suggest that tumor heterogeneity, and not technological lim-
tations alone, may  explain the tissue–plasma discordance and
he ‘reduced’ T790 M speciﬁcity observed with the plasma assays.
790M tumor heterogeneity has been reported of late, with differ-
nt tumor biopsies within the same patient demonstrating differing
GFR mutational proﬁles [1,2]. In all, these data suggest that plasma
tDNA may  be more precise and informative than tissue as the
lood mirrors the entire tumor burden [2]; additionally, a single
iopsy is often taken from a non-progressing lesion. However, het-
rogeneous tumors may  harbor additional resistance mechanisms
nd thus ultimately result in lower clinical response rates. Sup-
orting this concept, in patients with plasma positive but tumor
egative for T790M, the clinical ORR was 38% (three/eight patients)
nd the disease control rate was 75% (six/eight patients). These data
ppear more reﬂective of the clinical responses observed in patients
umor negative for T790M and thus suggest the potential for tumor
eterogeneity, albeit with the caveat of involving a small number
f patient samples.
Plasma ctDNA has potential in the management of patients with
SCLC in routine clinical practice, particularly considering that DNA
xtraction and mutation detection using a commercially available
nd approved test could be performed in as little as 1 day [14,32],
llowing for real-time disease testing. That said, robust validation
n prospective clinical trials [16,33], such as that planned in the
URA program, is required.
In conclusion, multiple platforms are capable of sensitive and
peciﬁc detection of EGFR-TKI-sensitizing mutations from ctDNA
n patients with NSCLC. The cobas® EGFR Mutation Test assay and
EAMing dPCR showed highly concordant T790M resistance muta-
ion detection, with 70–80% sensitivity, using a tissue test result
s a non-reference standard, for genotyping. Genomic heterogene-
ty of T790M-mediated resistance may  account for the reduced
peciﬁcity observed with plasma- versus tissue-based detection.
he rate of clinical response to AZD9291 was almost identical in
atients positive for the T790M mutation in plasma and in tissue,
ndicating that plasma detection may  be a suitable alternative to
issue genotyping in patients with NSCLC.
Collectively, the results support the potential use of both plat-
orms in the AZD9291 clinical development program.
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